Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Illumina

Illumina Sheds Light, Divests its Cancer Tester, Grail

Illumina, a beacon in genetic science, is set to unfurl its stake in Grail-the stellar creator of cancer-detecting tests–in a dance of corporate divestiture.

AI will live up to the hype and more unicorns will lose their horns: 10 health care predictions for 2024 from top investors

AI will live up to the hype and more unicorns will lose their horns: 10 health care predictions for 2024 from top investors

Top health care investors Bob Kocher and Bryan Roberts share their annual predictions for the sector–and how last year's list panned out.

DNA-Reading Giant Illumina Crashes As Macro Pressures Guidance — Again

DNA-Reading Giant Illumina Crashes As Macro Pressures Guidance — Again

Illumina stock crashed Friday after the DNA-reading behemoth slashed its outlook as pressures continue to build on life sciences companies.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

The Independent UK

Dow Jones Futures Rise After Nasdaq, Nvidia Break Support In AI Sell-Off; Inflation Data Due

The Nasdaq and Nvidia fell below their 50-day moving averages, with AI stocks tumbling. Inflation data is on tap. Here's what to do now.

Investors Business Daily

Illumina Recovers After Torching Its 2023 Outlook; Announces A 'Huge Accomplishment'

Illumina stock recovered Thursday after the company torched its guidance on continuing headwinds. ILMN stock briefly retook its 50-day line.

Investors Business Daily

Inside Illumina’s bruising proxy battle with billionaire activist investor Carl Icahn

Illumina’s contentious acquisition of cancer test maker Grail brought billionaire Carl Icahn to the company’s doorstep.

inkl

Read news from The Economist, FT, and more,
with one subscription

EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

The European Union has slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog

The Independent UK

Cancer vaccines are already a reality. Here's what you need to know about the cutting-edge technology that could usher in an era of personalized medicine

Cancer vaccines are already a reality. Here's what you need to know about the cutting-edge technology that could usher in an era of personalized medicine

The concept may seem torn from the plot of some futuristic sci-fi movie, or from the pages of some decades-old utopian novel far ahead of its time. But such wonders of science exist today.

Illumina’s Sudden CEO Exit Is Just One of Many Problems Facing DNA Company

The sudden resignation of Francis deSouza raises questions about the firm’s future after its proxy fight with Carl Icahn.

Primate genome study reveals evolutionary traits, human uniqueness and disease mutations

Primate genome study reveals evolutionary traits, human uniqueness and disease mutations

CCMB team, along with international scientists, conducted genome sequencing of 809 individuals from 233 primate species, covering nearly half of all existing primate species on earth

Studying Primates Sheds Light On Causes Of Common Diseases

Scientists mapped the DNA of over 800 individuals from 233 primate species.

Carl Icahn’s activist play plays into the hands of Lina Khan and EU regulators

Carl Icahn’s activist play plays into the hands of Lina Khan and EU regulators

Every company with acquisition plans in the U.S. and Europe should be concerned about the FTC partnering with EU regulators to sink the Illumina-Grail deal.

DNA sequencing platform hit by serious security flaws

DNA sequencing platform hit by serious security flaws

One of the two vulnerabilities discovered carries a 10/10 severity score.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review

The stock market rally went to "under pressure" amid big earnings moves and revived banking fears, but the major indexes ultimately closed tightly again.

Investors Business Daily

Dow Jones Reverses Lower As Microsoft Surges On Earnings; Tesla Stock Slides On Downgrade; Facebook Earnings Next

The Dow Jones rose Wednesday, as Microsoft surged on earnings. Tesla stock was downgraded. And Facebook earnings are next.

Investors Business Daily

Illumina Stock Tumbles As Sales, Profits Decline — Why The First-Quarter Beat Has 'Mixed Implications'

DNA-sequencing leader Illumina eked out a first-quarter beat, but ILMN stock toppled Wednesday on its cloudy future.

Investors Business Daily

FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle

The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell on the news.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Backlog in NHS genome service leaves families facing long wait for results

Exclusive: Experts say delays of more than a year risk children not getting relevant treatments or support

Investors Business Daily

Illumina Surges As Activist Investor Carl Icahn Attempts To Wrest Control

Activist investor Carl Icahn is fighting for control of Illumina after the acquisition of Grail. In response, ILMN stock surged Monday.

Investors Business Daily

Dow Jones Reverses On SVB Rescue Plan; First Republic, Charles Schwab Crash On Bank Fears

The Dow Jones fell Monday, as the FDIC guaranteed all deposits of SVB Financial. First Republic crashed 75% on ongoing bank fears.

It takes an average of 8 years for a rare disease patient to get diagnosed. Why is it so hard to get life-altering genetic testing in the U.S.?

An increasingly inexpensive genetic test stands in the way of a diagnosis for many rare disease patients, who are as common as one in 10 worldwide.

Investors Business Daily

The Wild Card That Keeps Haunting DNA-Reading Giant Illumina

Illumina beat sales estimates, but profit came in light during the fourth quarter. That led ILMN stock to fall Wednesday.

Cancer vaccines are already a reality—but your doctor might not tell you about them unless you ask

“Patients need to advocate for themselves."

ChatGPT shows that the A.I. revolution has arrived. We’re not ready

Even more than social media, generative A.I. could disrupt business models and society itself. It's time to ask the tough questions.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,721 stories

102,275 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play